三生国健安沐奇塔单抗注射液新药上市申请获批准

Core Viewpoint - The approval of the new drug application for the monoclonal antibody Anmucita (trade name: Yisaituo) by the National Medical Products Administration marks a significant milestone for the company, enhancing its product pipeline in the autoimmune sector and strengthening its market competitiveness [1] Group 1 - The company has received approval for Anmucita, a humanized monoclonal antibody targeting IL-17A, for the treatment of moderate to severe plaque psoriasis in adult patients suitable for systemic therapy or phototherapy [1] - The approval is expected to enrich the company's commercial product pipeline in the autoimmune segment, positively impacting its operational development [1]